Article Cited by others


Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

Bailey Tameka A, Luan Haitao, Clubb Robert J, Naramura Mayumi, Band Vimla, Raja Srikumar M, Band Hamid

Year : 2011| Volume: 10| Issue : 1 | Page no: 28-28

   This article has been cited by
1 A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer
Seungyoon Nam,Hae Ryung Chang,Hae Rim Jung,Youme Gim,Nam Youl Kim,Regis Grailhe,Haeng Ran Seo,Hee Seo Park,Curt Balch,Jinhyuk Lee,Inhae Park,So Youn Jung,Kyung-Chae Jeong,Garth Powis,Han Liang,Eun Sook Lee,Jungsil Ro,Yon Hui Kim
Cancer Letters. 2014;
[Pubmed]  [Google Scholar] [DOI]
2 Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re
Mohamed Altai,Hadis Honarvar,Helena Wållberg,Joanna Strand,Zohreh Varasteh,Maria Rosestedt,Anna Orlova,Finn Dunås,Mattias Sandström,John Löfblom,Vladimir Tolmachev,Stefan Ståhl
European Journal of Medicinal Chemistry. 2014; 87: 519
[Pubmed]  [Google Scholar] [DOI]
3 Targeted therapy for HER2 positive breast cancer
Jason A Incorvati,Shilpan Shah,Ying Mu,Janice Lu
Journal of Hematology & Oncology. 2013; 6(1): 38
[Pubmed]  [Google Scholar] [DOI]
4 Adaptive Immune Responses and HER2/neu-Positive Breast Cancer
Eric D. Mortenson,Yang-Xin Fu
Current Pathobiology Reports. 2013; 1(1): 37
[Pubmed]  [Google Scholar] [DOI]
5 Targeted therapy for HER2 positive breast cancer
Incorvati, J.A. and Shah, S. and Mu, Y. and Lu, J.
Journal of Hematology and Oncology. 2013; 6(1)
[Pubmed]  [Google Scholar]
6 Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients
Sameer Mirza,Emad A. Rakha,Alaa Alshareeda,Shakur Mohibi,Xiangshan Zhao,Bryan J. Katafiasz,Jun Wang,Channabasavaiah Basavaraju Gurumurthy,Aditya Bele,Ian O. Ellis,Andrew R. Green,Hamid Band,Vimla Band
Breast Cancer Research and Treatment. 2013; 137(3): 721
[Pubmed]  [Google Scholar] [DOI]
7 Integrin a3ß1–CD151 complex regulates dimerization of ErbB2 via RhoA
V Novitskaya,H Romanska,R Kordek,P Potemski,R Kusinska,M Parsons,E Odintsova,F Berditchevski
Oncogene. 2013;
[Pubmed]  [Google Scholar] [DOI]
8 PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
Mattia Barbareschi,Lucia Veronica Cuorvo,Salvatore Girlando,Emma Bragantini,Claudio Eccher,Elena Leonardi,Antonella Ferro,Alessia Caldara,Renza Triolo,Chiara Cantaloni,Nicola Decarli,Enzo Galligioni,Paolo Dalla Palma
Virchows Archiv. 2012; 461(2): 129
[Pubmed]  [Google Scholar] [DOI]
9 What is the mechanism of progression with trastuzumab treatment - Escape or resistance?
Şendur, M.A.N. and Aksoy, S. and Özdemir, N.Y. and Zengin, N. and Altundag̀, K.
Asian Pacific Journal of Cancer Prevention. 2012; 13(11): 5915-5916
[Pubmed]  [Google Scholar]
10 PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
Barbareschi, M. and Cuorvo, L.V. and Girlando, S. and Bragantini, E. and Eccher, C. and Leonardi, E. and Ferro, A. and Caldara, A. and Triolo, R. and Cantaloni, C. and Decarli, N. and Galligioni, E. and Dalla Palma, P.
Virchows Archiv. 2012; 461(2): 129-139
[Pubmed]  [Google Scholar]
11 Toward individualized breast cancer therapy: Translating biological concepts to the bedside
Hortobagyi, G.N.
Oncologist. 2012; 17(4): 577-584
[Pubmed]  [Google Scholar]
12 Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance
Rita Nahta
Chemotherapy Research and Practice. 2012; 2012: 1
[Pubmed]  [Google Scholar] [DOI]


Read this article